Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL131381 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL19534323 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29356918 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4034 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL13420262 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL12313065 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL1501486 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4164613 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4450369 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647126-A2 | STABILIZING CAMPTOTHECIN PHARMACEUTICAL COMPOSITIONS | Ipsen Biopharm Ltd. (GB) | 2025-11-12 | — | — | EP | claimed |
| US-20240358706-A1 | Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin | IPSEN BIOPHARM LTD. (GB) | 2024-10-31 | — | — | US | claimed |
| US-20240342162-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies | IPSEN BIOPHARM LTD. (GB) | 2024-10-17 | — | — | US | claimed |
| US-20240226090-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan | IPSEN BIOPHARM LTD. (GB) | 2024-07-11 | — | — | US | claimed |
| CN-118284600-A | Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof | 曙方(上海)医药科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | claimed |
| US-11844795-B2 | Combination therapy for cancer treatment | IPSEN BIOPHARM LTD. | 2023-12-19 | — | — | US | claimed |
| CN-113993507-B | Pharmaceutical composition for oral administration comprising irinotecan free base | 大化制药株式会社 | 2023-08-01 | — | — | CN | claimed |
| CN-116120274-A | Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof | 曙方(上海)医药科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| US-20230088999-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies | IPSEN BIOPHARM LTD. (GB) | 2023-03-23 | — | — | US | claimed |
| US-20230074866-A1 | Combination Therapy for Cancer Treatment | IPSEN BIOPHARM LTD. (GB) | 2023-03-09 | — | — | US | claimed |
| US-20230000858-A1 | Nanoliposomal Irinotecan for Use in Treating Small Cell Lung Cancer | IPSEN BIOPHARM LTD. (GB) | 2023-01-05 | — | — | US | claimed |
| US-20220354799-A1 | SOLID ORAL DOSAGE FORM OF IRINOTECAN FOR THE TREATMENT OF CANCER | ONCORAL PHARMA APS (DK) | 2022-11-10 | — | — | US | claimed |
| US-20220313684-A1 | PHARMACEUTICAL COMPOSITION COMPRISING IRINOTECAN FREE BASE FOR ORAL ADMINISTRATION | DAE HWA PHARMA. CO., LTD. (KR) | 2022-10-06 | — | — | US | claimed |
| US-11369597-B2 | Methods for treating pancreatic cancer using combination therapies | IPSEN BIOPHARM LTD. | 2022-06-28 | — | — | US | claimed |
| WO-2022120490-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | claimed |
| US-11318131-B2 | Nanoliposomal irinotecan for use in treating small cell lung cancer | IPSEN BIOPHARM LTD. | 2022-05-03 | — | — | US | claimed |
| US-20220096458-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan | IPSEN BIOPHARM LTD. (GB) | 2022-03-31 | — | — | US | claimed |
| CN-114073678-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-113993507-A | Pharmaceutical composition for oral administration comprising irinotecan free base | 大化制药株式会社 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354799-A1 | SOLID ORAL DOSAGE FORM OF IRINOTECAN FOR THE TREATMENT OF CANCER | SI, SLC10A2, TOP1 | TOP1 3/4885GLA 4018/4885GAA 3309/4885 |
| US-20240342162-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies | PNLIP, RNASE1, LPXN | TOP1 171/4885GLA 2219/4885GAA 1208/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TOP1 3/4885GLA 1569/4885GAA 992/4885 |
| US-11369597-B2 | Methods for treating pancreatic cancer using combination therapies | PNLIP, RNASE1, LPXN | TOP1 171/4885GLA 2219/4885GAA 1208/4885 |
| US-11844795-B2 | Combination therapy for cancer treatment | TOP1, TOP2A, PARP2 | TOP1 1/4885GLA 2631/4885GAA 1473/4885 |
| US-20230074866-A1 | Combination Therapy for Cancer Treatment | TOP1, TOP2A, PARP2 | TOP1 1/4885GLA 2631/4885GAA 1473/4885 |
| US-20230088999-A1 | Methods For Treating Pancreatic Cancer Using Combination Therapies | PNLIP, RNASE1, LPXN | TOP1 171/4885GLA 2219/4885GAA 1208/4885 |
| US-20220313684-A1 | PHARMACEUTICAL COMPOSITION COMPRISING IRINOTECAN FREE BASE FOR ORAL ADMINISTRATION | SLC10A2, SI, SLC19A1 | TOP1 8/4885GLA 4050/4885GAA 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.